Q1 2025 Management View CEO Eric Dube reported strong progress for the quarter, highlighting FILSPARI's foundational role in treating IgA nephropathy (IgAN). Net sales of FILSPARI increased 13% ...

Despite a significant increase in net sales, Travere Therapeutics Inc (TVTX) faces hurdles with a reported net loss and ...

Shares of Travere Therapeutics were trading at $20.08 as of April 29. Over the last 52-week period, shares are up 236.04%.

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2025 financial results and provided a corporate update.

Travere Therapeutics (TVTX) reported $81.73 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 97.6%. EPS of -$0.47 for the same period compares to -$1.76 a ...

The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 55 cents per share. The drug developer posted revenue of $81.7 ...

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing ...

TVTX opened at $18.33 on Monday. Travere Therapeutics, Inc. has a twelve month low of $5.24 and a twelve month high of $25.29. The firm has a market cap of $1.63 billion, a price-to-earnings ratio ...

Welcome to the Travere Therapeutics' first-quarter 2025 financial results conference call. Today's call is being recorded. At this time, I would like to turn the conference call over to Victoria ...

Analysts are estimating that Agios Pharmaceuticals will report an earnings per share (EPS) of $-1.76. The announcement from ...

SAN DIEGO & ST. GALLEN, Switzerland--(BUSINESS WIRE)--Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor are pleased to announce that the European Commission has approved the conversion of ...